1
00:00:03,200 --> 00:00:11,240
Speaker 1: From Bloomberg News and iHeartRadio. It's the big take. I'm Wescasova. Today.

2
00:00:11,360 --> 00:00:15,800
Speaker 1: New drugs to treat obesity really work. The question is

3
00:00:15,920 --> 00:00:25,639
Speaker 1: who will get them and who won't. There's been a

4
00:00:25,640 --> 00:00:29,200
Speaker 1: lot of news coverage lately about ozepic and other drugs

5
00:00:29,400 --> 00:00:32,160
Speaker 1: like it that are shown to be effective at helping

6
00:00:32,240 --> 00:00:36,360
Speaker 1: people living with obesity to lose weight. The downside, you

7
00:00:36,479 --> 00:00:39,839
Speaker 1: often have to stay on them, and they are expensive

8
00:00:40,040 --> 00:00:44,120
Speaker 1: thousands of dollars a year. Some insurance companies are reluctant

9
00:00:44,120 --> 00:00:47,800
Speaker 1: to cover them, even with a doctor's prescription. And this

10
00:00:48,000 --> 00:00:51,680
Speaker 1: is stirring up all kinds of questions about taking obesity

11
00:00:51,760 --> 00:00:55,400
Speaker 1: seriously as a disease and about how healthcare is often

12
00:00:55,600 --> 00:00:57,880
Speaker 1: very different from people who can afford to pay for

13
00:00:57,960 --> 00:01:00,480
Speaker 1: costly treatments and those who can't.

14
00:01:00,720 --> 00:01:02,840
Speaker 2: And now you know, we're at a point where people

15
00:01:02,880 --> 00:01:05,640
Speaker 2: are more accepting of it is more about people's chemistry

16
00:01:05,680 --> 00:01:07,759
Speaker 2: than about their character, right, This is not a character

17
00:01:07,760 --> 00:01:11,120
Speaker 2: of law. This is a biochemical process that creates the

18
00:01:11,160 --> 00:01:13,520
Speaker 2: disease of obesity, just like you know, similar to what

19
00:01:13,720 --> 00:01:16,319
Speaker 2: was a struggle for mental health for very many years

20
00:01:16,440 --> 00:01:19,160
Speaker 2: until there was an increased awareness and increased focus.

21
00:01:19,680 --> 00:01:23,760
Speaker 1: That's doctor Angela Fitch. She specializes in treating obesity, and

22
00:01:23,800 --> 00:01:27,200
Speaker 1: we're going to hear more from her later in the show. First,

23
00:01:27,240 --> 00:01:30,720
Speaker 1: Bloomberg reporters am A Court and Robert Langreth. They've been

24
00:01:30,760 --> 00:01:34,520
Speaker 1: covering the upsides and downsides of these medications and the

25
00:01:34,600 --> 00:01:39,319
Speaker 1: back and forth over who should foot the bill. Emma,

26
00:01:39,360 --> 00:01:42,440
Speaker 1: can you start by telling us how do these drugs work?

27
00:01:43,360 --> 00:01:45,800
Speaker 3: The drugs have a bunch of different names. I think

28
00:01:45,840 --> 00:01:49,560
Speaker 3: people are maybe most familiar with ozembic, which is actually

29
00:01:49,640 --> 00:01:51,240
Speaker 3: not specifically a.

30
00:01:51,480 --> 00:01:52,520
Speaker 4: Drug for weight loss.

31
00:01:52,520 --> 00:01:55,040
Speaker 3: It's a drug for diabetes that happens to produce some

32
00:01:55,080 --> 00:01:58,560
Speaker 3: weight loss. Basically, there's a group of these drugs ozempic.

33
00:01:59,200 --> 00:02:02,000
Speaker 3: The one that's been specifically approved for obesity right now

34
00:02:02,080 --> 00:02:05,480
Speaker 3: is called Wagovi. There's an earlier one called Sexenda. There's

35
00:02:05,520 --> 00:02:09,200
Speaker 3: one that's sort of going through the regulatory process soon

36
00:02:09,280 --> 00:02:13,120
Speaker 3: for obesity called Munjaro. These drugs are all part of

37
00:02:13,120 --> 00:02:17,040
Speaker 3: a class called GLP one receptor agonists, and basically the

38
00:02:17,040 --> 00:02:19,960
Speaker 3: way they work is they help people feel full, they

39
00:02:20,040 --> 00:02:24,639
Speaker 3: eat less, and people lose weight. The catches that people

40
00:02:24,680 --> 00:02:26,720
Speaker 3: may need to take them long term to keep the

41
00:02:26,720 --> 00:02:29,120
Speaker 3: weight loss off they've done some studies where people quit

42
00:02:29,160 --> 00:02:32,480
Speaker 3: taking the drugs and they regained a lot of weight.

43
00:02:33,080 --> 00:02:35,799
Speaker 3: But the main factor here to think about is these

44
00:02:35,800 --> 00:02:39,600
Speaker 3: are drugs that replicate a hormone that exists naturally, but

45
00:02:39,840 --> 00:02:43,680
Speaker 3: at pretty high pharmaceutical levels of sort of mimicking this

46
00:02:43,720 --> 00:02:47,320
Speaker 3: hormone in the body, and it comes with some side effects.

47
00:02:47,600 --> 00:02:52,760
Speaker 3: A lot of people have nausea, diarrhea, constipation, but they're

48
00:02:52,760 --> 00:02:56,920
Speaker 3: considered relatively safe because they have been studied in diabetes

49
00:02:56,960 --> 00:02:57,680
Speaker 3: for many years.

50
00:02:58,720 --> 00:03:02,359
Speaker 5: The interesting thing to me watching the pharmaceutical industry for

51
00:03:02,440 --> 00:03:05,200
Speaker 5: so many years, there's been a long history of attempts

52
00:03:05,200 --> 00:03:07,680
Speaker 5: to develop weight loss drugs that have run into lots

53
00:03:07,680 --> 00:03:11,040
Speaker 5: of problems or have been many examples of previous weight

54
00:03:11,080 --> 00:03:14,480
Speaker 5: loss pills that had to have recalls for safety reasons.

55
00:03:14,880 --> 00:03:17,440
Speaker 5: This class, which is showing, you know, more efficacy than

56
00:03:17,480 --> 00:03:20,480
Speaker 5: previous weight loss drugs before, in some sense, kind of

57
00:03:20,480 --> 00:03:22,280
Speaker 5: came out of left field. It really came out of

58
00:03:22,320 --> 00:03:26,160
Speaker 5: diabetes research. These GLP and hormones that they're essentially mimicking

59
00:03:26,200 --> 00:03:28,160
Speaker 5: in these drugs. It turns out that in addition to

60
00:03:28,320 --> 00:03:30,920
Speaker 5: helping regulate blood sugar, which is the reason they were

61
00:03:30,919 --> 00:03:34,720
Speaker 5: originally discovered these hormones also have important roles in sending

62
00:03:34,880 --> 00:03:37,280
Speaker 5: fullness signals to the brain. And when they did some

63
00:03:37,360 --> 00:03:39,720
Speaker 5: of the early trials or the early versions of these

64
00:03:39,800 --> 00:03:43,040
Speaker 5: drugs and diabetes, you know, they discover that people with

65
00:03:43,120 --> 00:03:46,560
Speaker 5: diabetes they lost weight, but for a long time that

66
00:03:46,800 --> 00:03:50,800
Speaker 5: wasn't the main focus the research and drug companies didn't

67
00:03:51,040 --> 00:03:54,040
Speaker 5: until recently really pursue the weight loss angle of them

68
00:03:54,080 --> 00:03:56,800
Speaker 5: as an O B city standalone agent. So that's only

69
00:03:56,840 --> 00:04:01,360
Speaker 5: started accelerating recently as they've developed much more potent, longer

70
00:04:01,400 --> 00:04:03,960
Speaker 5: acting versions of these drugs and lo and behold, when

71
00:04:04,000 --> 00:04:06,880
Speaker 5: they did that, the amount of weight loss that was

72
00:04:06,880 --> 00:04:09,120
Speaker 5: produced in some of these trials, you know, went up dramatically,

73
00:04:09,160 --> 00:04:12,240
Speaker 5: and that's kind of the big surprise. It has tons

74
00:04:12,280 --> 00:04:14,560
Speaker 5: of drug company executive just like you know, almost like

75
00:04:14,600 --> 00:04:17,120
Speaker 5: salivating over the potential enormous market size.

76
00:04:18,600 --> 00:04:20,359
Speaker 1: How much weight can you lose on them? Like? How

77
00:04:20,440 --> 00:04:24,200
Speaker 1: much more effective are they than previous efforts to make

78
00:04:24,240 --> 00:04:25,159
Speaker 1: a weight loss drug.

79
00:04:25,880 --> 00:04:28,960
Speaker 5: Well, there are some of the most significantly effective drugs

80
00:04:28,960 --> 00:04:31,279
Speaker 5: of single agents that have ever been developed from what

81
00:04:31,320 --> 00:04:34,560
Speaker 5: we see so far, especially the newer ones and some

82
00:04:34,600 --> 00:04:37,360
Speaker 5: of those with GOVI, which is Nova Noordius drug, which

83
00:04:37,400 --> 00:04:40,640
Speaker 5: is a higher dose version of a zempeic that produces

84
00:04:40,680 --> 00:04:44,000
Speaker 5: around thirty pounds of weight loss. And Eli Lilly has

85
00:04:44,040 --> 00:04:48,280
Speaker 5: a diabetes drug called Munjaro that's also testing for obesity,

86
00:04:48,720 --> 00:04:51,360
Speaker 5: and in their early big trial, in their first big

87
00:04:51,400 --> 00:04:55,240
Speaker 5: trial of that drug, that produced at high doses around

88
00:04:55,240 --> 00:04:57,279
Speaker 5: fifty pounds of weight loss, which is kind of like

89
00:04:57,360 --> 00:05:00,440
Speaker 5: almost an unprecedented thing, you know, for a single drug

90
00:05:00,440 --> 00:05:02,920
Speaker 5: and a big trial. The sense is like almost all

91
00:05:02,960 --> 00:05:05,000
Speaker 5: sorts of drug companies just kind of racing to get

92
00:05:05,000 --> 00:05:05,520
Speaker 5: in the field.

93
00:05:06,360 --> 00:05:09,240
Speaker 1: They clearly work, but there's kind of a big downside.

94
00:05:09,279 --> 00:05:12,400
Speaker 1: They are not cheap, is that right, Emma?

95
00:05:12,520 --> 00:05:15,479
Speaker 3: Yeah, So these drugs, you know, depending on which specific

96
00:05:15,560 --> 00:05:18,960
Speaker 3: drugs you're talking about, like the class generally costs more

97
00:05:19,000 --> 00:05:22,560
Speaker 3: than ten thousand dollars a year, with GOV specifically is

98
00:05:22,600 --> 00:05:25,919
Speaker 3: more like seventeen thousand dollars a year. And you know,

99
00:05:26,000 --> 00:05:30,360
Speaker 3: typically insurance pays for medication, right, I mean, they don't

100
00:05:30,360 --> 00:05:32,480
Speaker 3: pay for everything, and they might give you a hard time,

101
00:05:32,600 --> 00:05:35,560
Speaker 3: but if you have a disease, typically you know, you

102
00:05:35,600 --> 00:05:38,960
Speaker 3: can get insurance coverage for treatments, you know, more or less.

103
00:05:39,520 --> 00:05:43,240
Speaker 3: In this case, though, obesity is treated pretty differently from

104
00:05:43,279 --> 00:05:46,560
Speaker 3: other conditions, and that there isn't like sort of routine,

105
00:05:46,680 --> 00:05:49,520
Speaker 3: regular coverage for weight loss drugs. And so, you know,

106
00:05:49,560 --> 00:05:52,240
Speaker 3: we found in like our reporting that you know, whether

107
00:05:52,279 --> 00:05:54,680
Speaker 3: you're looking at private insurers, like if you work at

108
00:05:54,680 --> 00:05:57,240
Speaker 3: a big company and you have private insurance, whether you're

109
00:05:57,360 --> 00:06:00,800
Speaker 3: getting insurance through Medicare, which is for elderly people in

110
00:06:00,839 --> 00:06:04,000
Speaker 3: the US, to get health insurance coverage Medicaid, which is

111
00:06:04,040 --> 00:06:09,040
Speaker 3: for low income people, generally, coverage is really really spotty.

112
00:06:09,200 --> 00:06:13,080
Speaker 3: You know, a minority of insurers are covering drugs like

113
00:06:13,120 --> 00:06:16,839
Speaker 3: these for weight loss. Medicare isn't covering it at all,

114
00:06:17,360 --> 00:06:20,360
Speaker 3: and there's been a big push from pharma to try

115
00:06:20,400 --> 00:06:21,280
Speaker 3: to change that.

116
00:06:21,880 --> 00:06:26,560
Speaker 5: We surveyed all fifty states Medicaid plans and only roughly

117
00:06:26,600 --> 00:06:30,200
Speaker 5: eleven states provided you know, broad coverage for BC drugs,

118
00:06:30,240 --> 00:06:34,640
Speaker 5: and many many states excluded it entirely. Private insurance coverage

119
00:06:34,720 --> 00:06:36,680
Speaker 5: was maybe a little bit better, but it varies all

120
00:06:36,720 --> 00:06:40,000
Speaker 5: over the map. Roughly from the surveys, we see maybe

121
00:06:40,040 --> 00:06:43,880
Speaker 5: a quarter of private plans we'll cover BCD drugs. It's

122
00:06:43,880 --> 00:06:46,400
Speaker 5: one of those rare categories in the US. Insurance feel

123
00:06:46,400 --> 00:06:49,720
Speaker 5: they can just like blanket not cover and not get

124
00:06:49,760 --> 00:06:50,599
Speaker 5: too much pushback.

125
00:06:51,000 --> 00:06:53,240
Speaker 3: So what that means is if you're a person and

126
00:06:53,279 --> 00:06:55,839
Speaker 3: you have a body mass index of over a certain

127
00:06:55,880 --> 00:06:59,280
Speaker 3: threshold for OBCD it's thirty plus. So you go to

128
00:06:59,400 --> 00:07:04,240
Speaker 3: the doctor, your doctor weighs you, they say, you have obesity.

129
00:07:04,480 --> 00:07:07,960
Speaker 3: We're going to prescribe you this new, cutting edge medication

130
00:07:08,160 --> 00:07:11,320
Speaker 3: that works really well to help people lose weight. You

131
00:07:12,280 --> 00:07:15,080
Speaker 3: try to get that prescription covered by insurance, and it

132
00:07:15,160 --> 00:07:17,960
Speaker 3: is going to be a big battle, and chances are

133
00:07:18,320 --> 00:07:19,560
Speaker 3: you're going to lose that battle.

134
00:07:20,760 --> 00:07:24,280
Speaker 1: Bob. What is the insurance industry's reason for not covering

135
00:07:24,280 --> 00:07:24,880
Speaker 1: these drugs.

136
00:07:25,400 --> 00:07:28,720
Speaker 5: One of the reasons is simply cost. There's roughly half

137
00:07:28,760 --> 00:07:31,600
Speaker 5: the adult population would qualify under the label, under the

138
00:07:31,640 --> 00:07:34,640
Speaker 5: official FDA label you know, for these drugs, So if

139
00:07:34,720 --> 00:07:37,960
Speaker 5: everyone used it that could potentially qualify, the costs would

140
00:07:38,000 --> 00:07:42,840
Speaker 5: just be enormous. Some industry financial analyst estimates are estimating

141
00:07:42,880 --> 00:07:45,640
Speaker 5: that this class of drugs could eventually have sales of

142
00:07:45,680 --> 00:07:48,320
Speaker 5: one hundred and fifty billion dollars a year between obesity

143
00:07:48,320 --> 00:07:50,640
Speaker 5: and diabetes, like basically making one of the best selling

144
00:07:50,680 --> 00:07:53,000
Speaker 5: you know, classes of drugs ever.

145
00:07:53,560 --> 00:07:55,800
Speaker 3: You know. I think another piece of it is they

146
00:07:55,840 --> 00:07:58,080
Speaker 3: don't have to cover it. There is a precedent for

147
00:07:58,120 --> 00:08:01,760
Speaker 3: not covering it. Medicare doesn't cover it. Medicare is sort

148
00:08:01,800 --> 00:08:04,960
Speaker 3: of the gold standard for coverage, right. If Medicares cover something,

149
00:08:05,400 --> 00:08:09,600
Speaker 3: private insurers typically follow. But it's interesting because there is

150
00:08:10,040 --> 00:08:14,280
Speaker 3: pressure already to cover the stuff, and it's going to

151
00:08:14,520 --> 00:08:18,400
Speaker 3: only increase as you know, Novo Nordisk, the maker of

152
00:08:18,520 --> 00:08:22,360
Speaker 3: ozembic and magov puts more money into this fight. You know,

153
00:08:22,400 --> 00:08:25,560
Speaker 3: if Eli Lilly gets approved for obesity, you're going to

154
00:08:25,640 --> 00:08:29,200
Speaker 3: have more and more companies coming into this space, lobbying

155
00:08:29,240 --> 00:08:33,800
Speaker 3: in Washington to change coverage, pushing private plans. You already

156
00:08:33,800 --> 00:08:37,040
Speaker 3: have patients going to their HR office and saying, you know,

157
00:08:37,520 --> 00:08:40,040
Speaker 3: why don't you cover with goov? You know, my companies

158
00:08:40,400 --> 00:08:42,400
Speaker 3: to have this great health insurance. You know, I'm paying

159
00:08:42,400 --> 00:08:44,760
Speaker 3: top dollar for why aren't you paying for this drug?

160
00:08:45,679 --> 00:08:45,920
Speaker 4: You know.

161
00:08:45,960 --> 00:08:48,600
Speaker 5: One of the points that insurers make is that, yes,

162
00:08:48,679 --> 00:08:50,839
Speaker 5: these drugs do cause a lot of weight loss. Are

163
00:08:50,880 --> 00:08:53,760
Speaker 5: not disputing that, but they say that the drugs, you know,

164
00:08:53,920 --> 00:08:57,360
Speaker 5: haven't been proven to reduce you know, kind of hard

165
00:08:57,679 --> 00:09:01,800
Speaker 5: clinical health outcomes, like they haven't been proven to reduce

166
00:09:01,840 --> 00:09:04,120
Speaker 5: heart attacks and strokes, So they haven't been proven to

167
00:09:04,120 --> 00:09:07,560
Speaker 5: reduce sleep apnea or other complications of obesity, and the

168
00:09:07,600 --> 00:09:10,679
Speaker 5: insurers are right about that. And what the drug companies

169
00:09:10,679 --> 00:09:13,319
Speaker 5: are doing in response is they're actually doing so called

170
00:09:13,400 --> 00:09:16,760
Speaker 5: outcomes trials trying to prove that if you give their

171
00:09:16,840 --> 00:09:19,520
Speaker 5: drugs to someone who's a bee that though, you'll reduce

172
00:09:19,559 --> 00:09:21,920
Speaker 5: the rate of heart attacks and strokes, or you'll prevent

173
00:09:22,040 --> 00:09:24,800
Speaker 5: complications of sleep apnea, or in someone who is abese

174
00:09:24,840 --> 00:09:27,559
Speaker 5: with heart failure, to prevent heart failure related events. So

175
00:09:27,600 --> 00:09:29,720
Speaker 5: they're trying to do that and those trials, which should

176
00:09:29,760 --> 00:09:32,240
Speaker 5: start reading out as soon as this summer, those are

177
00:09:32,240 --> 00:09:35,000
Speaker 5: going to be very, very important to determine what kind

178
00:09:35,040 --> 00:09:37,840
Speaker 5: of coverage that these drugs get over the long term.

179
00:09:38,040 --> 00:09:40,040
Speaker 3: And this kind of speaks to the bigger question of

180
00:09:40,160 --> 00:09:44,720
Speaker 3: like what is obesity? Is obesity inherently a disease? And

181
00:09:44,760 --> 00:09:48,440
Speaker 3: about a decade ago, the American Medical Association said, yeah,

182
00:09:48,520 --> 00:09:51,440
Speaker 3: obesity is a disease. And part of the reason they

183
00:09:51,480 --> 00:09:54,520
Speaker 3: did that is they wanted doctors to start diagnosing it,

184
00:09:54,559 --> 00:09:57,840
Speaker 3: they wanted health insurance to start paying for it. What's

185
00:09:57,880 --> 00:10:01,000
Speaker 3: interesting about that is if obesity is a disease, then

186
00:10:01,200 --> 00:10:04,800
Speaker 3: weight loss alone might be enough to make a difference

187
00:10:04,800 --> 00:10:09,000
Speaker 3: with this disease. You don't normally see a company having

188
00:10:09,040 --> 00:10:11,880
Speaker 3: to run more trials than just this sort of initial

189
00:10:11,880 --> 00:10:14,760
Speaker 3: trial to get coverage like this, Like this shows that

190
00:10:14,840 --> 00:10:17,559
Speaker 3: the bar for proving these drugs work.

191
00:10:17,760 --> 00:10:20,920
Speaker 4: Is higher, and question about why is it higher?

192
00:10:20,920 --> 00:10:23,040
Speaker 3: You know, I think some people would say this is stigma,

193
00:10:23,120 --> 00:10:25,720
Speaker 3: this is discrimination, But I think there is a really

194
00:10:25,760 --> 00:10:27,960
Speaker 3: interesting question at the heart of this of you know,

195
00:10:28,080 --> 00:10:31,360
Speaker 3: many many people in America are considered to have quote

196
00:10:31,440 --> 00:10:35,560
Speaker 3: unquote excess weight. But are all those people sick? Well,

197
00:10:35,559 --> 00:10:37,440
Speaker 3: we know a lot of them aren't, right. We know

198
00:10:37,640 --> 00:10:42,160
Speaker 3: many people with these higher BMIs don't necessarily have all

199
00:10:42,160 --> 00:10:45,719
Speaker 3: these other diseases, right, They don't necessarily have diabetes or

200
00:10:45,800 --> 00:10:49,760
Speaker 3: heart disease. And it gets into all these thorny, complicated,

201
00:10:50,040 --> 00:10:51,319
Speaker 3: difficult questions.

202
00:10:52,360 --> 00:10:55,079
Speaker 1: After the break, with so much demand for these drugs,

203
00:10:55,160 --> 00:11:07,240
Speaker 1: will the price start to come down? Emma, you report

204
00:11:07,240 --> 00:11:11,120
Speaker 1: that obesity can sometimes get in the way of doctor's

205
00:11:11,320 --> 00:11:15,480
Speaker 1: ability to treat people for serious illnesses. What did you find?

206
00:11:16,600 --> 00:11:19,559
Speaker 3: Something that is not super well known is that there

207
00:11:19,600 --> 00:11:25,040
Speaker 3: are body mass index limits, often for medical equipment. So

208
00:11:25,080 --> 00:11:27,880
Speaker 3: if you're trying to get certain kinds of scans you

209
00:11:27,960 --> 00:11:30,200
Speaker 3: might not be able to if you you know way

210
00:11:30,280 --> 00:11:35,679
Speaker 3: too much. There are also body mass index limits for procedures,

211
00:11:35,679 --> 00:11:39,360
Speaker 3: often and you know, ostensibly to make them less risky.

212
00:11:39,960 --> 00:11:43,480
Speaker 3: Carolina Povian, who's a obesity doctor at Brigham and Women's

213
00:11:43,520 --> 00:11:47,600
Speaker 3: Hospital in Boston, told us she has patients who because

214
00:11:47,640 --> 00:11:53,200
Speaker 3: of their body mass index, can't qualify for literally organ transplants.

215
00:11:53,360 --> 00:11:57,880
Speaker 3: We're talking heart transplants. People can't qualify for because of

216
00:11:57,920 --> 00:12:00,760
Speaker 3: their body mass index. And yet they they also can't

217
00:12:00,760 --> 00:12:03,520
Speaker 3: get access to a drug that would help them unless

218
00:12:03,520 --> 00:12:06,520
Speaker 3: they're quite wealthy or they work at a company with

219
00:12:06,600 --> 00:12:08,240
Speaker 3: exceptional insurance benefits.

220
00:12:08,679 --> 00:12:12,040
Speaker 5: There have been some big wins for the Coalition to

221
00:12:12,120 --> 00:12:15,120
Speaker 5: Doctors and advocates and companies are pushing for better coverage.

222
00:12:15,120 --> 00:12:18,280
Speaker 5: And one of the most concrete examples of improving coverage

223
00:12:18,320 --> 00:12:21,120
Speaker 5: is the Federal Employee Benefits Plan, and that's a big

224
00:12:21,360 --> 00:12:24,520
Speaker 5: cluster of plans that covers federal employees. We're talking eight

225
00:12:24,559 --> 00:12:27,080
Speaker 5: million people are in this. The federal government this year

226
00:12:27,120 --> 00:12:30,240
Speaker 5: put out a rule that is requiring insurers in that

227
00:12:30,360 --> 00:12:33,520
Speaker 5: plan to cover at least one of these GLP one

228
00:12:33,640 --> 00:12:36,280
Speaker 5: drugs for BC. That's a big change that adds a

229
00:12:36,280 --> 00:12:38,000
Speaker 5: lot of people onto the coverage roles.

230
00:12:38,440 --> 00:12:41,480
Speaker 3: We also found in our analysis of state medicaid plans,

231
00:12:41,520 --> 00:12:44,520
Speaker 3: So this is Medicaid is the program that ensures low

232
00:12:44,559 --> 00:12:46,880
Speaker 3: income individuals in the US, and it varies a lot

233
00:12:46,920 --> 00:12:47,720
Speaker 3: by state to state.

234
00:12:48,080 --> 00:12:50,440
Speaker 4: And what we found as part of this is policies

235
00:12:50,480 --> 00:12:51,080
Speaker 4: are changing.

236
00:12:51,120 --> 00:12:54,200
Speaker 3: So a couple of states have actually started covering obcit

237
00:12:54,320 --> 00:12:57,360
Speaker 3: drugs in recent years. A bunch of states, about eight

238
00:12:57,440 --> 00:13:00,400
Speaker 3: told us that they're actually looking at maybe covering So

239
00:13:00,800 --> 00:13:03,720
Speaker 3: it does seem like things are changing incrementally.

240
00:13:04,600 --> 00:13:08,280
Speaker 1: What did the drug companies say about why these drugs

241
00:13:08,280 --> 00:13:09,080
Speaker 1: are so expensive.

242
00:13:10,120 --> 00:13:12,120
Speaker 5: I've done a lot of reporting on drug pricing over

243
00:13:12,160 --> 00:13:14,360
Speaker 5: the years, and I found when you ask a company

244
00:13:14,400 --> 00:13:16,880
Speaker 5: you know about the price, it's very hard to get

245
00:13:16,880 --> 00:13:19,640
Speaker 5: a clear answer why they price it the way they do.

246
00:13:19,720 --> 00:13:22,040
Speaker 5: But you know what Eli Lilly and Novadora say is,

247
00:13:22,200 --> 00:13:25,480
Speaker 5: you know, the price of the drugs reflects the value

248
00:13:26,200 --> 00:13:29,720
Speaker 5: and clinical benefits that they provide. Now, I will note

249
00:13:29,720 --> 00:13:33,040
Speaker 5: that the Munjaro that's Eli Lilly's drug, is only approved

250
00:13:33,120 --> 00:13:35,640
Speaker 5: right now for a diabetes, So they're talking about diabetes.

251
00:13:36,040 --> 00:13:39,520
Speaker 5: And there's another strange aspect of the pricing that's going

252
00:13:39,559 --> 00:13:43,120
Speaker 5: on in that Novo Nordisk when it came out with

253
00:13:43,200 --> 00:13:45,560
Speaker 5: a higher dose version of a zempic called the GOVI

254
00:13:45,760 --> 00:13:49,040
Speaker 5: that's only approved for obesity, it decided to price it

255
00:13:49,080 --> 00:13:52,360
Speaker 5: about forty percent higher than ozempic, even though it's just

256
00:13:52,400 --> 00:13:55,000
Speaker 5: a modestly higher dose of exactly the same drug.

257
00:13:55,480 --> 00:13:56,760
Speaker 1: And why do they say they did that?

258
00:13:57,320 --> 00:13:59,800
Speaker 4: We asked Novo Nordisk about this.

259
00:14:00,320 --> 00:14:03,680
Speaker 3: Basically what they say is that with gov is more

260
00:14:03,679 --> 00:14:08,360
Speaker 3: effective than their previous weight loss drug called Sexenda.

261
00:14:08,920 --> 00:14:10,480
Speaker 4: You know, that's why they priced it that way.

262
00:14:10,960 --> 00:14:15,280
Speaker 3: One common answer as well, it's a higher dose than nozepic.

263
00:14:14,760 --> 00:14:17,000
Speaker 4: But it's not that much of a higher dose.

264
00:14:18,760 --> 00:14:21,280
Speaker 1: As you continue to cover this, what are you looking for?

265
00:14:21,320 --> 00:14:22,880
Speaker 1: What do you think comes next?

266
00:14:23,360 --> 00:14:26,280
Speaker 5: Well, I want to see will any of these other attempts,

267
00:14:26,360 --> 00:14:29,000
Speaker 5: you know, develop other follow on drugs, Will any of

268
00:14:29,000 --> 00:14:31,120
Speaker 5: them come to fruition, Like one of the things that

269
00:14:31,280 --> 00:14:33,560
Speaker 5: could help will be something that's not an injection that

270
00:14:33,600 --> 00:14:35,880
Speaker 5: could be taken as a pill on. You know, some

271
00:14:35,920 --> 00:14:38,000
Speaker 5: other drug companies like fives are working on but it's

272
00:14:38,320 --> 00:14:40,760
Speaker 5: not clear whether those are going to have as much efficacy.

273
00:14:41,000 --> 00:14:42,920
Speaker 5: So we'll get to know that in a few years.

274
00:14:43,480 --> 00:14:44,840
Speaker 3: I do think there's going to be a lot of

275
00:14:44,840 --> 00:14:48,080
Speaker 3: pressure to expand insurance coverage. I also think there's gonna

276
00:14:48,080 --> 00:14:49,920
Speaker 3: be a lot of resistance to paying for it. It

277
00:14:49,960 --> 00:14:52,600
Speaker 3: feels like things are going to come to a boil

278
00:14:52,680 --> 00:14:53,280
Speaker 3: pretty soon.

279
00:14:54,400 --> 00:14:56,880
Speaker 1: Emma, Bob, thanks so much for coming on the show.

280
00:14:57,440 --> 00:14:58,720
Speaker 4: Thank you, thank you.

281
00:14:59,400 --> 00:15:02,240
Speaker 1: When we come back, I talked to a physician about

282
00:15:02,240 --> 00:15:06,200
Speaker 1: these weight loss drugs and the challenges of treating obesity.

283
00:15:14,760 --> 00:15:18,480
Speaker 1: Let's hear now from someone who confronts these questions every day.

284
00:15:18,840 --> 00:15:23,160
Speaker 1: Doctor Angela Fitch specializes in the treatment of obesity. She's

285
00:15:23,280 --> 00:15:27,400
Speaker 1: president of the Obesity Medical Association, and I caught up

286
00:15:27,440 --> 00:15:31,680
Speaker 1: with her at the group's spring conference in New York City. Angela,

287
00:15:31,760 --> 00:15:37,400
Speaker 1: the American Medical Association ten years ago classified obesity as

288
00:15:37,600 --> 00:15:40,880
Speaker 1: a disease. What is the importance of this distinction?

289
00:15:41,880 --> 00:15:45,400
Speaker 2: So obesity really is a disease like other chronic diseases,

290
00:15:45,880 --> 00:15:49,320
Speaker 2: and the path of physiology behind it is much more

291
00:15:49,360 --> 00:15:53,920
Speaker 2: complicated than just the idea of eating less and moving more. Right,

292
00:15:53,920 --> 00:15:57,280
Speaker 2: there's a lot of diseases hypertension, high cholesterol, heart disease

293
00:15:57,800 --> 00:16:01,400
Speaker 2: that have lifestyle factors involved with them. But for many

294
00:16:01,480 --> 00:16:05,480
Speaker 2: years it was felt even by personally, by patients, by society,

295
00:16:05,840 --> 00:16:08,680
Speaker 2: that obesity was just people's fault, that it was just

296
00:16:08,720 --> 00:16:11,400
Speaker 2: their own responsibility, and that they were just eating too

297
00:16:11,480 --> 00:16:14,520
Speaker 2: much and not moving enough. And so this importance of

298
00:16:14,560 --> 00:16:17,080
Speaker 2: classifying it as a disease was that it really is

299
00:16:17,120 --> 00:16:20,280
Speaker 2: a disease because it's more complicated than just eating less

300
00:16:20,320 --> 00:16:23,640
Speaker 2: and moving more and the AMA you know, declaring it

301
00:16:23,680 --> 00:16:26,640
Speaker 2: a disease in twenty thirteen, you know, that's a long

302
00:16:26,680 --> 00:16:28,920
Speaker 2: time ago, but over the course of this time, I

303
00:16:28,960 --> 00:16:32,080
Speaker 2: really feel like we're finally at an awareness currently that

304
00:16:32,160 --> 00:16:34,120
Speaker 2: it is a disease. You know, I liken it to

305
00:16:34,160 --> 00:16:37,400
Speaker 2: mental health issues as well. For longest time, people didn't

306
00:16:37,400 --> 00:16:40,080
Speaker 2: think depression or anxiety or other types of mental health

307
00:16:40,080 --> 00:16:42,360
Speaker 2: issues was a disease state. It was more of just

308
00:16:42,440 --> 00:16:45,160
Speaker 2: a you know, the person's own issue that they're dealing with.

309
00:16:45,240 --> 00:16:47,720
Speaker 2: It was very stigmatizing, and now you know, we're at

310
00:16:47,760 --> 00:16:50,120
Speaker 2: a point where people are more accepting of it is

311
00:16:50,280 --> 00:16:53,080
Speaker 2: more about people's chemistry than about their character, right, This

312
00:16:53,200 --> 00:16:56,000
Speaker 2: is not a character law. This is a biochemical process

313
00:16:56,440 --> 00:16:58,920
Speaker 2: that creates the disease of obesity, just like you know,

314
00:16:58,920 --> 00:17:01,680
Speaker 2: similar to what was a struggle for mental health for

315
00:17:01,800 --> 00:17:04,399
Speaker 2: very many years until there was an increased awareness and

316
00:17:04,400 --> 00:17:08,160
Speaker 2: an increased focus on treating the disease in a comprehensive

317
00:17:08,240 --> 00:17:09,960
Speaker 2: chronic disease management fashion.

318
00:17:11,160 --> 00:17:15,360
Speaker 1: You mentioned treating the disease. How does classifying obesity as

319
00:17:15,359 --> 00:17:18,080
Speaker 1: a disease change the treatment? What are the practical effects

320
00:17:18,080 --> 00:17:18,320
Speaker 1: of that?

321
00:17:18,760 --> 00:17:22,320
Speaker 2: Yeah, because what we're leveraging for is better insurance coverage.

322
00:17:22,640 --> 00:17:27,000
Speaker 2: We're leveraging for coverage of the whole spectrum of the

323
00:17:27,119 --> 00:17:33,399
Speaker 2: disease process, from lifestyle management to medications, pharmacotherapy to bartic surgery,

324
00:17:33,400 --> 00:17:36,879
Speaker 2: which is a very comprehensive approach to the treatment of

325
00:17:36,920 --> 00:17:39,240
Speaker 2: a disease state. You know, much like cancer. You have

326
00:17:39,560 --> 00:17:43,080
Speaker 2: a surgery for cancer, you have chemotherapy, you have radiation treatment,

327
00:17:43,240 --> 00:17:45,639
Speaker 2: you have mental health treatment, you have lifestyle treatment that

328
00:17:45,680 --> 00:17:48,480
Speaker 2: affects cancer. You know, a lot of cancer centers offer

329
00:17:49,080 --> 00:17:51,880
Speaker 2: yoga and other types of mindfulness based treatment to help

330
00:17:51,920 --> 00:17:54,520
Speaker 2: their patients live a longer, healthier life. And a lot

331
00:17:54,600 --> 00:17:57,000
Speaker 2: of those times, those types of services can be covered

332
00:17:57,160 --> 00:18:01,359
Speaker 2: under certain plans or by employers because of the fact

333
00:18:01,359 --> 00:18:04,360
Speaker 2: that they are part of the overall comprehensive disease treatment.

334
00:18:04,720 --> 00:18:08,159
Speaker 2: So it's about gaining access for patients, you know, access

335
00:18:08,160 --> 00:18:11,040
Speaker 2: to coverage for these services by their insurance versus having

336
00:18:11,040 --> 00:18:14,600
Speaker 2: to pay for so long, obesity was something patients were

337
00:18:14,600 --> 00:18:16,840
Speaker 2: expected to pay out of pocket for in order to

338
00:18:16,880 --> 00:18:18,280
Speaker 2: get access to that care.

339
00:18:19,040 --> 00:18:23,040
Speaker 1: The treatment that we're talking about today are obesity drugs,

340
00:18:23,040 --> 00:18:26,240
Speaker 1: this new class of drug that seems to be very effective.

341
00:18:27,000 --> 00:18:30,200
Speaker 1: Are you using these drugs in your own practice?

342
00:18:30,640 --> 00:18:33,119
Speaker 2: Yes, I've been practicing obest medicine. Now. I was a

343
00:18:33,119 --> 00:18:36,840
Speaker 2: primary care physician double bordered in inter medicine and pediatric,

344
00:18:36,880 --> 00:18:39,440
Speaker 2: so I see the full spectrum of the disease from

345
00:18:40,119 --> 00:18:43,600
Speaker 2: young childhood, you know, through even older adulthood, so that

346
00:18:43,680 --> 00:18:47,680
Speaker 2: full spectrum of treatment. You know, we offer pharmacotherapy as

347
00:18:47,760 --> 00:18:50,880
Speaker 2: part of that treatment in the appropriate patient that it's

348
00:18:50,880 --> 00:18:54,919
Speaker 2: indicated for, because it is much more effective than lifestyle alone.

349
00:18:55,119 --> 00:18:56,800
Speaker 2: You know, a person with a blood pressure of one

350
00:18:56,880 --> 00:18:59,440
Speaker 2: hundred and eighty over one hundred in my office, you know,

351
00:18:59,480 --> 00:19:02,680
Speaker 2: I'm not going to just recommend lifestyle therey to start with,

352
00:19:03,000 --> 00:19:06,399
Speaker 2: because that person has a disease burden of hypertension that

353
00:19:06,520 --> 00:19:09,920
Speaker 2: is so strong for them, whether that's genetic or environmental,

354
00:19:10,119 --> 00:19:13,119
Speaker 2: or maybe they have one kidney because they lost one

355
00:19:13,160 --> 00:19:15,199
Speaker 2: in surgery. You know, the point is that they have

356
00:19:15,280 --> 00:19:18,040
Speaker 2: a disease state that's bothering them, and if we don't

357
00:19:18,040 --> 00:19:20,439
Speaker 2: treat it with a medication, they might have a stroke

358
00:19:20,560 --> 00:19:22,359
Speaker 2: or a heart attack or some other thing happen.

359
00:19:22,640 --> 00:19:23,360
Speaker 4: And the same is.

360
00:19:23,280 --> 00:19:25,800
Speaker 2: True as obesti as a disease. You know, this has

361
00:19:25,840 --> 00:19:28,840
Speaker 2: a lessyle component to it that is effective, but also

362
00:19:29,080 --> 00:19:32,639
Speaker 2: it's much more effective. We're talking ten times more effective

363
00:19:32,920 --> 00:19:35,879
Speaker 2: to reach your goals by adding pharmaco therapy, which is

364
00:19:36,000 --> 00:19:39,959
Speaker 2: very similar to other chronic diseases that we manage diabetes, hypertension,

365
00:19:40,000 --> 00:19:44,240
Speaker 2: cardiovath but disease, etc. Biologically, as humans, we are not

366
00:19:44,440 --> 00:19:47,560
Speaker 2: designed to lose weight. It goes against everything in mother

367
00:19:47,680 --> 00:19:50,199
Speaker 2: nature for us to lose weight. It's not the normal

368
00:19:50,240 --> 00:19:53,840
Speaker 2: process for us. So trying to alter mother nature takes

369
00:19:53,880 --> 00:19:56,800
Speaker 2: more than usually what we can sort of will away,

370
00:19:56,840 --> 00:19:57,359
Speaker 2: if you will.

371
00:19:59,040 --> 00:20:02,120
Speaker 1: What's been your exp eperiencing trying to get coverage for

372
00:20:02,280 --> 00:20:05,880
Speaker 1: patients you prescribe these drugs, so it is very variable.

373
00:20:05,880 --> 00:20:08,520
Speaker 2: I'm very fortunate that in New England where I'm practicing

374
00:20:08,600 --> 00:20:12,879
Speaker 2: right now, we have excellent coverage by our commercial payers.

375
00:20:13,080 --> 00:20:14,840
Speaker 2: So one of the things that we're trying to fix

376
00:20:14,880 --> 00:20:17,439
Speaker 2: here at the OBC Medicine Association for which I'm president

377
00:20:17,520 --> 00:20:20,919
Speaker 2: right now, is advocate that obese treatment would be a

378
00:20:20,960 --> 00:20:24,320
Speaker 2: standard benefit on the insurance plan right now, the problem

379
00:20:24,400 --> 00:20:27,080
Speaker 2: across the country and all commercial payers is that it's

380
00:20:27,119 --> 00:20:30,639
Speaker 2: not a standard benefit, so employers have to choose to

381
00:20:30,720 --> 00:20:35,680
Speaker 2: add it for an extra cost onto their coverage. Employers

382
00:20:35,680 --> 00:20:37,439
Speaker 2: sometimes don't do that, they don't know they have to

383
00:20:37,480 --> 00:20:39,439
Speaker 2: do it. Maybe there's a lot of reasons, you know,

384
00:20:39,560 --> 00:20:40,000
Speaker 2: for that.

385
00:20:40,800 --> 00:20:43,480
Speaker 1: In recent years, we've seen the rise of a body

386
00:20:43,520 --> 00:20:46,440
Speaker 1: positivity movement, which says that just because you have a

387
00:20:46,520 --> 00:20:48,960
Speaker 1: large body doesn't mean that you're sick. That there are

388
00:20:49,000 --> 00:20:52,720
Speaker 1: people who are obese under the clinical definition but lead

389
00:20:52,800 --> 00:20:56,080
Speaker 1: healthy lives, and there's people who are not clinically obese

390
00:20:56,119 --> 00:20:58,960
Speaker 1: who have diseases. What is your view on that.

391
00:21:00,320 --> 00:21:01,960
Speaker 2: I would say that one thing we're trying to work

392
00:21:02,000 --> 00:21:04,200
Speaker 2: on too is to get rid of the word obese

393
00:21:04,200 --> 00:21:07,919
Speaker 2: from our vocabulary, because what we talk about is obese

394
00:21:08,000 --> 00:21:10,240
Speaker 2: sort of defines a person by their disease, and we

395
00:21:10,280 --> 00:21:13,600
Speaker 2: don't like to use that terminology. And so when you

396
00:21:13,680 --> 00:21:15,840
Speaker 2: have the disease of obesity, it's a disease that you

397
00:21:15,920 --> 00:21:18,240
Speaker 2: have and you live with It's not something that sort

398
00:21:18,240 --> 00:21:21,280
Speaker 2: of defines you, like I am an obese person, right,

399
00:21:21,320 --> 00:21:25,000
Speaker 2: that sort of defines who I am versus I have obesity.

400
00:21:25,119 --> 00:21:27,720
Speaker 2: The disease, as you pointed out, not everybody has the

401
00:21:27,760 --> 00:21:30,919
Speaker 2: same severity of the disease is the issue. So what

402
00:21:30,960 --> 00:21:35,240
Speaker 2: we're really looking at is identifying what each individual person's

403
00:21:35,320 --> 00:21:37,760
Speaker 2: risk factor is related to that disease, like we do

404
00:21:37,840 --> 00:21:41,080
Speaker 2: with any disease state, and then deciding in an individual

405
00:21:41,160 --> 00:21:43,800
Speaker 2: shared decision making fashion between the patient and the clinician

406
00:21:44,280 --> 00:21:47,119
Speaker 2: if treatment is warranted for them at this time, because

407
00:21:47,119 --> 00:21:50,560
Speaker 2: even if they might be very healthy without other comorbidities,

408
00:21:50,680 --> 00:21:53,879
Speaker 2: their obesity may be preventing them from running around as

409
00:21:53,960 --> 00:21:56,920
Speaker 2: much at the playground with their grandchildren or fitting into

410
00:21:56,920 --> 00:21:59,040
Speaker 2: the airline seat when they're traveling a lot because that's

411
00:21:59,040 --> 00:22:01,919
Speaker 2: what they do for work. There's other reasons besides just

412
00:22:02,200 --> 00:22:06,080
Speaker 2: general health or metabolic health that people choose to make

413
00:22:06,160 --> 00:22:09,560
Speaker 2: changes to their weight, and they certainly should be accepted

414
00:22:09,600 --> 00:22:12,480
Speaker 2: no matter what size they are, so reducing the bias

415
00:22:12,520 --> 00:22:15,760
Speaker 2: and stigma around size is very important. At the same time,

416
00:22:15,760 --> 00:22:18,119
Speaker 2: if they want to change their size, they should have

417
00:22:18,200 --> 00:22:19,280
Speaker 2: the access to do that.

418
00:22:21,160 --> 00:22:24,879
Speaker 1: Is there a concern that if these drugs are so

419
00:22:24,960 --> 00:22:29,600
Speaker 1: widely available and are so effective that people will depend

420
00:22:29,680 --> 00:22:33,280
Speaker 1: on them instead of living a healthy lifestyle where they

421
00:22:33,280 --> 00:22:36,159
Speaker 1: eat well and they exercise, that this will become something

422
00:22:36,160 --> 00:22:40,119
Speaker 1: that actually exacerbates a problem instead of addressing the core cause.

423
00:22:40,880 --> 00:22:45,000
Speaker 2: We really are addressing the core cause with pharmacotherapy. Again,

424
00:22:45,080 --> 00:22:48,240
Speaker 2: to assume that the core cause is poor eating or

425
00:22:48,280 --> 00:22:51,959
Speaker 2: lack of physical activity is a biased assumption. Many people

426
00:22:52,040 --> 00:22:55,280
Speaker 2: living in larger bodies with obesity are very active. So

427
00:22:55,440 --> 00:22:58,440
Speaker 2: just assuming that someone has OBCs not active. I mean,

428
00:22:58,520 --> 00:23:01,800
Speaker 2: I have patients who the Boston Marathon recently, and I

429
00:23:01,840 --> 00:23:04,199
Speaker 2: didn't run the Boston Marathon. I can't do that, but

430
00:23:04,280 --> 00:23:06,360
Speaker 2: they can because that's what they do and they practice

431
00:23:06,400 --> 00:23:08,760
Speaker 2: for it. Right, And there's many people who eat a

432
00:23:08,840 --> 00:23:11,320
Speaker 2: very healthy lifestyle, and that's why it's a disease state.

433
00:23:11,680 --> 00:23:14,200
Speaker 2: You know, just like if you get cancer, right, it's

434
00:23:14,200 --> 00:23:16,200
Speaker 2: not your fault. It's not maybe something that you did,

435
00:23:16,200 --> 00:23:18,760
Speaker 2: maybe you didn't smoke, but at the same time you

436
00:23:18,880 --> 00:23:21,720
Speaker 2: ended up with lung cancer. Now that being said, we

437
00:23:21,840 --> 00:23:24,800
Speaker 2: all in the United States of America have to choose

438
00:23:24,880 --> 00:23:28,359
Speaker 2: to live differently than our current environment because our current

439
00:23:28,440 --> 00:23:32,720
Speaker 2: environment is very obesogenic. We have very large portion sizes,

440
00:23:32,840 --> 00:23:36,560
Speaker 2: we have more ultraprocessed food around us, we have less

441
00:23:36,560 --> 00:23:39,640
Speaker 2: physical activity. It's good for us to eat healthier, it's

442
00:23:39,680 --> 00:23:41,560
Speaker 2: good for us to eat more vegetables, to eat more

443
00:23:41,560 --> 00:23:44,199
Speaker 2: fiber and not eat the ultra processed food, right, but

444
00:23:44,280 --> 00:23:47,600
Speaker 2: it doesn't always treat the disease of obesity. So again

445
00:23:47,760 --> 00:23:51,119
Speaker 2: we need that comprehensive approach, and all of us at

446
00:23:51,119 --> 00:23:54,600
Speaker 2: the OBC Medicine Association that practice OBC medicine take a

447
00:23:54,640 --> 00:23:57,640
Speaker 2: comprehensive approach to treatment. You know, we're not just sort

448
00:23:57,680 --> 00:24:00,879
Speaker 2: of dolling out drugs, so to speak, talking about some

449
00:24:00,960 --> 00:24:03,960
Speaker 2: of these other lifestyle factors that are involved, because again

450
00:24:04,080 --> 00:24:07,880
Speaker 2: it's optimizing that whole patient journey. That is really what

451
00:24:07,960 --> 00:24:10,920
Speaker 2: all of us do as physicians and clinicians that practice

452
00:24:10,960 --> 00:24:13,760
Speaker 2: medicine every day, you know, with any issue that our

453
00:24:13,800 --> 00:24:16,919
Speaker 2: patients have, is to help them holistically, you know, to

454
00:24:16,960 --> 00:24:18,440
Speaker 2: reach their health and wellness goal.

455
00:24:19,359 --> 00:24:22,200
Speaker 1: Doctor Angela Fitch, thanks for speaking with me today.

456
00:24:22,760 --> 00:24:24,680
Speaker 2: Thank you so much, Bess as a pleasure.

457
00:24:25,160 --> 00:24:27,280
Speaker 1: Thanks for listening to us here at the Big Takes,

458
00:24:27,320 --> 00:24:30,920
Speaker 1: a daily podcast from Bloomberg and iHeartRadio for more shows

459
00:24:30,920 --> 00:24:34,720
Speaker 1: from my Heart Radio, visit the iHeartRadio app, Apple Podcasts,

460
00:24:34,800 --> 00:24:37,639
Speaker 1: or wherever you listen, and we'd love to hear from you.

461
00:24:37,720 --> 00:24:41,159
Speaker 1: Email us questions or comments to Big Take at Bloomberg

462
00:24:41,200 --> 00:24:45,040
Speaker 1: dot net. The supervising producer of The Big Take is

463
00:24:45,119 --> 00:24:49,920
Speaker 1: Vicky Vergalina. Our senior producer is Catherine Fink. Rebecca Shasson

464
00:24:50,080 --> 00:24:54,560
Speaker 1: is our producer. Our associate producer is Sam Gebauer. Raphael M.

465
00:24:54,600 --> 00:24:58,159
Speaker 1: Seely is our engineer. Our original music was composed by

466
00:24:58,240 --> 00:25:02,000
Speaker 1: Leo Sidrin. I'm Wescaso. We'll be back on Monday with

467
00:25:02,119 --> 00:25:04,360
Speaker 1: another Big Take. Have a great weekend.

468
00:25:05,560 --> 00:25:05,600
Speaker 3: M